Tag: #pharma-ai13 results
Temasek CEO Dilhan Pillay Sandrasegara predicts AI will profoundly impact pharma and biotech. He shared this view during a Bloomberg Invest discussion with Lisa Abramowicz. AI will not replace the need for software in these sectors.
AstraZeneca VP Chen Bing forecasts ongoing large BD deals for Chinese innovative drugs, driven by pipeline complementarity beyond crowded oncology to autoimmunity and cardiovascular fields. AI emerges as key enabler, boosting molecule screening, clinical optimization, and new indications. AstraZeneca highlights partnerships like CSPC for long-acting weight loss drugs.
At China's two sessions, pharma leaders like Sun Piaoyang highlight innovative drug hospital access issues and advocate AI integration in R&D, primary care, TCM, and obesity management. Suggestions include subsidies for AI doctor assistants and AI-driven breakthroughs in key technologies. This aims to enhance innovation conversion and grassroots healthcare.